Physician profile
Maria Gregory
NPI 1639148596
$13,281.66
in general payments reported to CMS, 2019-2025
46 companies · $1,564 in 2025
The $1,564 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $583 · 2020: $631 · 2021: $2,958 · 2022: $2,261 · 2023: $3,903 · 2024: $1,382 · 2025: $1,564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,563 · Consulting Fee: $175 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,562.62 |
| Consulting Fee | $175.00 |
| Education | $111.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $2,134.79 | 2021-2025 | Mavenclad, Mavenclad |
| Biogen, INC. | $1,463.78 | 2020-2025 | Vumerity, Tysabri, Tysabri |
| Alexion Pharmaceuticals, INC. | $1,175.79 | 2021-2025 | Ultomiris, Soliris |
| Ucb, INC. | $866.13 | 2019-2025 | Briviact, Rystiggo, Fintepla |
| Novartis Pharmaceuticals Corporation | $833.23 | 2020-2025 | |
| Sunovion Pharmaceuticals INC. | $756.59 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $734.17 | 2021-2025 | Nuplazid, Daybue |
| Abbvie INC. | $688.67 | 2021-2025 | |
| Horizon Therapeutics Plc | $599.45 | 2022-2023 | Uplizna |
| Genentech USA, INC. | $342.51 | 2021-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Lundbeck LLC | $327.83 | 2020-2024 | Vyepti |
| Corium, LLC | $259.47 | 2023 | Adlarity, Azstarys |
| Banner Life Sciences, LLC | $219.92 | 2021-2022 | |
| Amgen INC. | $219.68 | 2022-2025 | Uplizna, Aimovig |
| Livanova USA, INC. | $191.16 | 2021-2023 | Vns Therapy Sentiva Model 1000 Generator |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Gregory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.